BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2001

View Archived Issues

European MAA submitted for Onzar in the treatment of cutaneous T-cell lymphoma

Read More

BMS submits NDA for Vanlev for the treatment of hypertension

Read More

Cangene seeks approval for antihepatitis B hyperimmune in Canada

Read More

FDA completes IND review of candidate anti-HIV drug TMC-125

Read More

Boehringer Ingelheim submits U.S. NDA for Spiriva in chronic obstructive pulmonary disease

Read More

Progen receives funding for malaria vaccine projects

Read More

Initiation of phase II trial of Ceplene in triple-drug combination therapy

Read More

Activax vaccine component enters clinical testing for prevention of travelers' diseases

Read More

Patient enrollment completed for phase III trial of Neovastat in renal cell carcinoma

Read More

Novartis Ophthalmics and Kissei enter license option agreement for novel glaucoma agent

Read More

Encouraging oral insulin results obtained with BioSante's CAP delivery system

Read More

Boehringer Ingelheim and Structural Bioinformatics jointly research HIV protein targets

Read More

TMC-114: preclinical and early clinical results discussed at ICAAC

Read More

Broad-spectrum antiherpesvirus agents presented by Pharmacia in Chicago

Read More

DNA-interacting compounds under development at GeneSoft as antibacterial agents

Read More

ICAAC news: more on efflux pump inhibitors in development at Essential Therapeutics and Daiichi

Read More

Data presented at this year's ICAAC meeting support continued development of anidulafungin

Read More

Bay-41-4109 characterized at ICAAC as a novel, promising anti-HBV agent

Read More

Update on clinical status of E-7070

Read More

Clinical-stage heart failure therapeutic available for licensing from Banyu

Read More

Urokinase inhibitors identified by Abbott as antiangiogenic agents

Read More

Abbott researchers present benzonitrile-based protein farnesyltransferase inhibitors

Read More

Potential new therapeutic agents for BPH in development at Merck

Read More

Indian researchers discover antimalarial compounds

Read More

NMDA receptor antagonists and their use disclosed by Roche

Read More

Promoters of fibrinolysis designed at Torii as new antithrombotic drugs

Read More

Japanese companies decide not to seek approval in Japan for clinprost

Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing